A Comparison of Recist 1.1 and the Side Effects of Neoadjuvant Chemotherapy Based on Anthracyclines and Taxane in Patients with Advanced Local-Stage Breast Cancer at Prof. Dr. R.D. Kandou General Hospital
DOI:
https://doi.org/10.46799/jhs.v7i8.2870Keywords:
advanced breast cancer, neoadjuvant chemotherapy, RECIST 1.1, chemotherapy side effectsAbstract
Breast cancer remains a major cause of cancer-related morbidity and mortality among women, and locally advanced disease continues to pose significant therapeutic challenges. Neoadjuvant chemotherapy is commonly administered to reduce tumor burden and improve surgical operability, with anthracycline- and taxane-based regimens being widely used. This study aimed to compare the effectiveness and adverse effects of anthracycline-based and taxane-based neoadjuvant chemotherapy in patients with locally advanced breast cancer at Prof. Dr. R. D. Kandou General Hospital. An observational analytic study with a prospective cohort design was conducted involving 27 female patients, comprising 11 patients who received anthracycline-based chemotherapy and 16 patients who received taxane-based chemotherapy. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, while adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). The results showed that partial response was the predominant outcome in both groups, occurring in 81.82% of patients in the anthracycline group and 75% of patients in the taxane group. The Mann–Whitney test revealed no significant difference in treatment effectiveness between the two regimens (p = 0.708). Most adverse effects were mild to moderate, although toxicity patterns differed between the groups. In conclusion, both regimens demonstrated comparable effectiveness, while treatment selection should consider patient characteristics, organ function, tolerability, and regimen-specific adverse-effect risks. These findings support individualized regimen selection based on therapeutic efficacy and anticipated toxicity profiles.
References
Arredondo, J., Pastor, E., Simó, V., Beltrán, M., Castañón, C., Magdaleno, M. C., Matanza, I., Notarnicola, M., & Ielpo, B. (2020). Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review. Techniques in Coloproctology, 24(10), 1001–1015.
Alkabban, F. M., & Ferguson, T. (2023). Breast cancer. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482286/
Andreopoulou, E., & Sparano, J. A. (2013). Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer: An overview. Current Breast Cancer Reports, 5(1), 42–50.
Arredondo, J., Pastor, E., Simó, V., Beltrán, M., Castañón, C., Magdaleno, M. C., Matanza, I., Notarnicola, M., & Ielpo, B. (2020). Neoadjuvant chemotherapy in locally advanced colon cancer: A systematic review. Techniques in Coloproctology, 24(10), 1001–1015.
Baselga, J., & Norton, L. (2002). Focus on breast cancer. Focus, 1(1), 319–322.
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 1–35.
Braybrooke, J., Bradley, R., Gray, R., Hills, R. K., Pan, H., Peto, R., et al. (2023). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: A patient-level meta-analysis of 100,000 women from 86 randomized trials. The Lancet, 401(10384), 1277–1292.
Chen, Y., Qi, Y., & Wang, K. (2023). Neoadjuvant chemotherapy for breast cancer: An evaluation of its efficacy and research progress. Frontiers in Oncology, 13, 1169010.
Dwyer, M. (2023, March 23). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast cancer (Version 4). National Comprehensive Cancer Network.
Gautama, W. (2022). Breast cancer in Indonesia in 2022: 30 years of marching in place. Indonesian Journal of Cancer, 16(1), 1.
Geng, B., Liang, M. M., Ye, X. B., & Zhao, W. Y. (2015). Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Molecular and Clinical Oncology, 3(1), 232–236.
Gouel, P., Callonnec, F., Levêque, É., Valet, C., Blôt, A., Cuvelier, C., et al. (2023). Evaluation of the capability and reproducibility of RECIST 1.1 measurements by technologists in breast cancer follow-up: A pilot study. Scientific Reports, 13(1).
Martin, M., Romero, A., Cheang, M. C. U., López García-Asenjo, J. A., García-Saenz, J. A., Oliva, B., et al. (2011). Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Research and Treatment, 128(1), 127–136.
Muley, H., Fadó, R., Rodríguez-Rodríguez, R., & Casals, N. (2020). Drug uptake-based chemoresistance in breast cancer treatment. Biochemical Pharmacology, 177, 1–14.
Ntellas, P., Spathas, N., Agelaki, S., Zintzaras, E., & Saloustros, E. (2019). Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: A pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. Oncotarget, 10(11), 1209–1216. https://www.oncotarget.com/
Rašić, A., Sofić, A., Bešlija, S., Rašić, I., & Hasanbegović, B. (2019). Effects of adding taxane to anthracycline-based neoadjuvant in locally advanced breast cancer. Medical Archives, 16(1), 77–82.
Rondonuwu, I. A., Haroen, H., & Wantania, F. E. (2016). Breast cancer profile at Prof. Dr. R. D. Kandou General Hospital, Manado, 2013–2014. e-CliniC, 4(1), 302–307.
Rusli, L. V., Merung, M., Pontoh, V., Manginstar, C., Hatibie, M. J., & Langi, F. L. F. G. (2021). Analysis of the relationship between CA 15-3 and neoadjuvant chemotherapy response in patients with locally advanced breast cancer. e-CliniC, 9(2), 466.
Sharma, G. N., Dave, R., Sanadya, J., Sharma, P., & Sharma, K. K. (2010). Various types and management of breast cancer: An overview. Journal of Advanced Pharmaceutical Technology & Research, 1(2), 109–126. https://www.japtr.org/
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023). Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy. Cancer Cell, 41(9), 1551–1566.
Tőkés, A. M., Vári-Kakas, S., Kulka, J., & Törőcsik, B. (2022). Tumor glucose and fatty acid metabolism in the context of anthracycline and taxane-based (neo)adjuvant chemotherapy in breast carcinomas. Frontiers in Oncology, 12, 1–23.
Yao, Z., Sun, B., Zhang, M., & Ge, P. (2026). The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A narrative review. Journal of Thoracic Disease, 18(1), 42.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Toby Hadinata Wiranegara, Marselus Merung, Denny Saleh
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aCreative Commons Attribution-ShareAlike 4.0 International (CC-BY-SA). that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
